SIRPA and neoplasm: Since hematological malignancies, including MM, express high CD47 levels, preclinical research demonstrated that an antibody-mediated blockade of CD47-SIRPα signaling could promote tumor cell death, phagocytosis and improve T-cell response [73,74,127,128].